BIODESIX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIODESIX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $71.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $49.09M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $38.21M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $54.51M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $45.56M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $24.55M | Mar 16, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.27M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($42.93M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($52.15M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($65.45M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($43.16M) | Mar 6, 2023 |
| FY2022 | Dec 31, 2020 | ($65.45M) | Mar 6, 2023 |
| FY2020 | Dec 31, 2019 | ($30.73M) | Mar 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.87M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($34.50M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($41.34M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($50.59M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($40.94M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($22.93M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($26.74M) | Mar 16, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.56M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $9.99M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $13.10M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.79M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $10.82M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $10.47M | Mar 16, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $80.45M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $67.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $61.46M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $50.52M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $34.86M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $30.64M | Mar 16, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.27M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($48.65M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($22.87M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($44.97M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($28.22M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($21.37M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($21.73M) | Mar 16, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.92M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $3.30M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.24M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $1.95M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.31M | Mar 16, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $97.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $99.10M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $92.91M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $76.10M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $121.07M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $45.03M | Mar 16, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $76.37M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $94.52M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $72.30M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $56.37M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $79.90M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $76.21M | Mar 16, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.47M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $20.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $20.61M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $19.73M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $41.17M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($225.14M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | ($194.63M) | Mar 16, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.03M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.03M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $15.03M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $15.03M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $15.03M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $15.03M | Mar 16, 2021 |
| FY2020 | Dec 31, 2018 | $14.20M | Mar 16, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($497.76M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($462.50M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($419.57M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($367.42M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($301.97M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($258.81M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($227.46M) | Mar 16, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $26.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $26.28M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $43.09M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $32.71M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $62.13M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $5.29M | Mar 16, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $40.03M | Mar 3, 2025 |
| FY2023 | Dec 31, 2023 | $40.08M | Mar 1, 2024 |
| FY2022 | Dec 31, 2022 | $30.13M | Mar 6, 2023 |
| FY2021 | Dec 31, 2021 | $10.08M | Mar 14, 2022 |
| FY2020 | Dec 31, 2020 | $28.08M | Mar 16, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 7.27M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 96.24M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 77.61M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 30.79M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 26.56M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 254,918 | Mar 16, 2021 |